过渡金属复合物的近期发展作为化疗低氧激活前药物 (HAP)
1Dept. of Chemistry, School of Advance Sciences, Vellore Institute of Technology, Vellore, 632014, India.
ChemMedChem
|April 18, 2024
概括
缺氧,瘤中低氧状态,促进癌症生长和治疗抵抗力. 过渡金属复合物被探索为低氧激活的前药物,在这些耐药瘤区域选择性释放抗癌药物.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 缺氧,以低氧水平为特征,在固体瘤中很普遍.
- 瘤缺氧导致异常的新血管化,血流不良和瘤细胞增多.
- 低毒性状况可以提高瘤的存活率和抗化学疗法和放射治疗的耐药性.
研究的目的:
- 对基于过渡金属的复合物作为低氧激活前期药物 (HAPs) 的最新研究进行审查.
- 突出HAPs在向和治疗缺氧瘤区域的潜力.
- 探索这些金属复合物的药物释放机制和抗癌活性.
主要方法:
- 在过去五年中发表的研究文章的文献综述.
- 专注于作为缺氧激活前药物设计的过渡金属复合物 (例如,Co,III,Pt,IV).
- 分析在低氧环境中从金属复合物中释放活性药物分子的减少触发的释放.
主要成果:
- 过渡金属复合物可以设计在低氧瘤微环境中减少.
- 减少导致活性药物联体的释放,使得向癌症治疗成为可能.
- 这种方法提供了一种战略,以克服与瘤缺氧相关的化疗和放射电阻.
结论:
- 基于过渡金属的低氧激活前期药物代表了癌症治疗的有希望的策略.
- 向减少瘤的环境允许控制药物释放和提高疗效.
- 这一领域的进一步研究可能会导致针对缺氧瘤的新型治疗药物.
相关概念视频
Electron Transport Chain: Complex I and II
13.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.1K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Phase I Oxidative Reactions: Overview
268
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
268
Drug Metabolism: Phase I Reactions
3.3K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.3K


